• Record revenue of A$3.4m
• Annual Recurring Revenue of A$13.7 million
• SOZO Core Business TCV of A$4.9 million
• Record cash receipts of A$4.1m

ImpediMed Limited (ASX.IPD) announced the release of the Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 31 March 2025 (Q3 FY25). The company recorded record unaudited total revenue of A$3.4 million for the quarter, up from A$3.3 million in the previous quarter. Annual Recurring Revenue (ARR) grew to A$13.7 million, up from A$12.5 million in the prior quarter. The Core Business Total Contracted Value (TCV) signed during the quarter was A$4.9 million, compared to A$3.2 million in the previous quarter. The company experienced record lead generation, with over 500 new leads identified, and is focused on converting these opportunities into sales. Net operating cash outflows for the quarter were A$3.5 million, which included record cash receipts from customers of A$4.1 million. The company ended the quarter with a total cash balance of A$27.9 million. The company announced the appointment of a new SVP of Sales, Scott Long, who brings extensive experience in the breast cancer medical device sales market.

The company is forecasting an additional one-off A$1.2m payment in Q4 FY25 to purchase key electronic components at pre-tariff pricing, to ensure continuity of supply.

Implementing the new go to market strategy is continuing, with increased scheduled media activity and conference attendance driving awareness and lead generation. With the new sales leadership and a measured investment in sales related personnel, the company expects a significant increase in SOZO unit sales over the balance of the calendar year.